The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma

Molecular Oncology

Volumn 9, Issue 3, 2015, Pages 657-674

  Montes de Oca, Rocío ^a,b,c,d   Gurard Levin, Zachary A ^a,b,c,d   Berger, Frédérique ^a,d,e   Rehman, Haniya ^a,b,c,d   Martel, Elise ^a   Corpet, Armelle ^a,b,c,d   de Koning, Leanne ^a,b,c,d   Vassias, Isabelle ^a,b,c,d   Wilson, Laurence O W ^a,b,c,d   Meseure, Didier ^a   Reyal, Fabien ^a   Savignoni, Alexia ^a,e   Asselain, Bernard ^a,e   Sastre Garau, Xavier ^a   Almouzni, Geneviève ^a,b,c,d  

^a INSTITUT CURIE   (France)

^b CNRS   (France)

^c INSTITUT CURIE   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e INSERM U900   (France)

Author keywords

Biomarkers; CENP A; Chromatin; Epigenetics; MKI67; Prognosis

Indexed keywords

CENTROMERE PROTEIN A; CHAPERONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HOLLIDAY JUNCTION RECOGNIZING PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN VARIANT; UNCLASSIFIED DRUG; ASF1B PROTEIN, HUMAN; AUTOANTIGEN; CELL CYCLE PROTEIN; CHROMATIN; DNA BINDING PROTEIN; HOLLIDAY JUNCTION RECOGNIZING PROTEIN, HUMAN; MCM2 PROTEIN, HUMAN; MINICHROMOSOME MAINTENANCE PROTEIN 2; NONHISTONE PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHROMATIN; CLINICAL DECISION MAKING; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSTIVIE BREAST CANCER; GENE CLUSTER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUMINAL A BREAST CARCINOMA; LUMINAL B BREAST CARCINOMA; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; BREAST TUMOR; CLASSIFICATION; CLUSTER ANALYSIS; COHORT ANALYSIS; DISEASE COURSE; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

AUTOANTIGENS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CHROMATIN; CHROMOSOMAL PROTEINS, NON-HISTONE; CLUSTER ANALYSIS; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 2; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 84923571339     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.11.002     Document Type: Article

References (78)

1. Abascal F., Corpet A., Gurard-Levin Z.A., Juan D., Ochsenbein F., Rico D., Valencia A., Almouzni G. Subfunctionalization via adaptive evolution influenced by genomic context: the case of histone chaperones ASF1a and ASF1b. Mol. Biol. Evol. 2013, 30:1853-1866.
2. Amato A., Schillaci T., Lentini L., Di Leonardo A. CENPA overexpression promotes genome instability in pRb-depleted human cells. Mol. Cancer 2009, 8:119.
3. Avvakumov N., Nourani A., Cote J. Histone chaperones: modulators of chromatin marks. Mol. Cell 2011, 41:502-514.
4. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., Salvesen H.B., Otte A.P., Akslen L.A. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J.Clin. Oncol. 2006, 24:268-273.
5. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11:726-734.
6. Berry D.A., Cirrincione C., Henderson I.C., Citron M.L., Budman D.R., Goldstein L.J., Martino S., Perez E.A., Muss H.B., Norton L., Hudis C., Winer E.P. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. J.Am. Med. Assoc. 2006, 295:1658-1667.
7. Boyarchuk E., Montes de Oca R., Almouzni G. Cell cycle dynamics of histone variants at the centromere, a model for chromosomal landmarks. Curr. Opin. Cell Biol. 2011, 23:266-276.
8. Boyarchuk E., Filipescu D., Vassias I., Cantaloube S., Almouzni G. The histone variant composition of centromeres is controlled by the pericentric heterochromatin state during the cell cycle. J.Cell Sci. 2014, 127:3347-3359.
9. Castellini P., Montironi M.A., Zizzi A., Scarpelli M., Mazzucchelli R., Lopez-Beltran A., Cheng L., Paone N., Montironi R. Recurrent papillary urothelial neoplasm of low malignant potential. Subtle architectural disorder detected by quantitative analysis in DAXX-immunostained tissue sections. Hum. Pathol. 2014, 45:745-752.
10. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., Watson M., Davies S., Bernard P.S., Parker J.S., Perou C.M., Ellis M.J., Nielsen T.O. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J.Natl. Cancer Inst. 2009, 101:736-750.
11. Chia S.K., Bramwell V.H., Tu D., Shepherd L.E., Jiang S., Vickery T., Mardis E., Leung S., Ung K., Pritchard K.I., Parker J.S., Bernard P.S., Perou C.M., Ellis M.J., Nielsen T.O. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin. Cancer Res. 2012, 18:4465-4472.
12. Cobleigh M.A., Tabesh B., Bitterman P., Baker J., Cronin M., Liu M.L., Borchik R., Mosquera J.M., Walker M.G., Shak S. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin. Cancer Res. 2005, 11:8623-8631.
13. Collett K., Eide G.E., Arnes J., Stefansson I.M., Eide J., Braaten A., Aas T., Otte A.P., Akslen L.A. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin. Cancer Res. 2006, 12:1168-1174.
14. Corpet A., De Koning L., Toedling J., Savignoni A., Berger F., Lemaitre C., O'Sullivan R.J., Karlseder J., Barillot E., Asselain B., Sastre-Garau X., Almouzni G. Asf1b, the necessary Asf1 isoform for proliferation, is predictive of outcome in breast cancer. EMBO J. 2011, 30:480-493.
15. Correa Geyer F., Reis-Filho J.S. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?. Int. J. Surg. Pathol. 2009, 17:285-302.
16. Cox D.R. Regression models and life-tables. J.R. Stat. Soc. Ser. 1972, B34:187-220.
17. Crea F., Fornaro L., Bocci G., Sun L., Farrar W.L., Falcone A., Danesi R. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev. 2012, 31:753-761.
18. de Cremoux P., Bieche I., Tran-Perennou C., Vignaud S., Boudou E., Asselain B., Lidereau R., Magdelenat H., Becette V., Sigal-Zafrani B., Spyratos F. Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction. Endocr. Relat. Cancer 2004, 11:489-495.
19. de Tayrac M., Saikali S., Aubry M., Bellaud P., Boniface R., Quillien V., Mosser J. Prognostic significance of EDN/RB, HJURP, p60/CAF-1 and PDLI4, four new markers in high-grade gliomas. PLoS One 2013, 8:e73332.
20. Dunleavy E.M., Roche D., Tagami H., Lacoste N., Ray-Gallet D., Nakamura Y., Daigo Y., Nakatani Y., Almouzni-Pettinotti G. HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell 2009, 137:485-497.
21. Elsheikh S.E., Green A.R., Rakha E.A., Powe D.G., Ahmed R.A., Collins H.M., Soria D., Garibaldi J.M., Paish C.E., Ammar A.A., Grainge M.J., Ball G.R., Abdelghany M.K., Martinez-Pomares L., Heery D.M., Ellis I.O. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 2009, 69:3802-3809.
22. Filipescu D., Szenker E., Almouzni G. Developmental roles of histone H3 variants and their chaperones. Trends Genetics 2013, 29:630-640.
23. Foltz D.R., Jansen L.E., Bailey A.O., Yates J.R., Bassett E.A., Wood S., Black B.E., Cleveland D.W. Centromere-specific assembly of CENP-a nucleosomes is mediated by HJURP. Cell 2009, 137:472-484.
24. Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin. Cancer Biol. 1990, 1:199-206.
25. Gerdes J., Schwab U., Lemke H., Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 1983, 31:13-20.
26. Giaginis C., Vgenopoulou S., Vielh P., Theocharis S. MCM proteins as diagnostic and prognostic tumor markers in the clinical setting. Histol. Histopathol. 2010, 25:351-370.
27. Gu X.M., Fu J., Feng X.J., Huang X., Wang S.M., Chen X.F., Zhu M.H., Zhang S.H. Expression and prognostic relevance of centromere protein A in primary osteosarcoma. Pathol. Res. Pract. 2014, 210:228-233.
28. Gurard-Levin Z.A., Almouzni G. Histone modifications and a choice of variant: a language that helps the genome express itself. F1000Prime Rep. 2014, 6:76-86.
29. Gurard-Levin Z.A., Quivy J.P., Almouzni G. Histone chaperones: assisting histone traffic and nucleosome dynamics. Annu. Rev. Biochem. 2014, 83:487-517.
30. Gyorffy B., Lanczky A., Eklund A.C., Denkert C., Budczies J., Li Q., Szallasi Z. An online survival analysis tool to assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res. Treat. 2010, 123:725-731.
31. Harbeck N., Sotlar K., Wuerstlein R., Doisneau-Sixou S. Molecular and protein markers for clinical decision making in breast cancer: today and tomorrow. Cancer Treat. Rev. 2014, 40:434-444.
32. Hu Z., Huang G., Sadanandam A., Gu S., Lenburg M.E., Pai M., Bayani N., Blakely E.A., Gray J.W., Mao J.H. The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Res. 2010, 12:R18.
33. Hua S., Kallen C.B., Dhar R., Baquero M.T., Mason C.E., Russell B.A., Shah P.K., Liu J., Khramtsov A., Tretiakova M.S., Krausz T.N., Olopade O.I., Rimm D.L., White K.P. Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol. Syst. Biol. 2008, 4:188.
34. Kato T., Sato N., Hayama S., Yamabuki T., Ito T., Miyamoto M., Kondo S., Nakamura Y., Daigo Y. Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res. 2007, 67:8544-8553.
35. Lacoste N., Woolfe A., Tachiwana H., Garea A.V., Barth T., Cantaloube S., Kurumizaka H., Imhof A., Almouzni G. Mislocalization of the centromeric histone variant CenH3/CENP-A in human cells depends on the chaperone DAXX. Mol. Cell 2014, 53:631-644.
36. Li Q., Birkbak N.J., Gyorffy B., Szallasi Z., Eklund A.C. Jetset: selecting the optimal microarray probe set to represent a gene. BMC Bioinformatics 2011, 12:474.
37. Li Y., Zhu Z., Zhang S., Yu D., Yu H., Liu L., Cao X., Wang L., Gao H., Zhu M. ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth. PLoS One 2011, 6:e17794.
38. Ma X.J., Salunga R., Tuggle J.T., Gaudet J., Enright E., McQuary P., Payette T., Pistone M., Stecker K., Zhang B.M., Zhou Y.X., Varnholt H., Smith B., Gadd M., Chatfield E., Kessler J., Baer T.M., Erlander M.G., Sgroi D.C. Gene expression profiles of human breast cancer progression. Proc. Natl. Acad. Sci. USA 2003, 100:5974-5979.
39. Maisonneuve P., Disalvatore D., Rotmensz N., Curigliano G., Colleoni M., Dellapasqua S., Pruneri G., Mastropasqua M.G., Luini A., Bassi F., Pagani G., Viale G., Goldhirsch A. A revised clinico-pathological surrogate definition of luminal A intrinsic breast cancer subtype. Breast Cancer Res. 2014, 16:R65.
40. McGovern S.L., Qi Y., Pusztai L., Symmans W.F., Buchholz T.A. Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res. 2012, 14:R72.
41. Mishra P.K., Au W.C., Choy J.S., Kuich P.H., Baker R.E., Foltz D.R., Basrai M.A. Misregulation of Scm3p/HJURP causes chromosome instability in Saccharomyces cerevisiae and human cells. PLoS Genet. 2011, 7:e1002303.
42. Mullan P.B., Millikan R.C. Molecular subtyping of breast cancer: opportunities for new therapeutic approaches. Cell Mol. Life Sci. 2007, 64:3219-3232.
43. Nielsen T., Wallden B., Schaper C., Ferree S., Liu S., Gao D., Barry G., Dowidar N., Maysuria M., Storhoff J. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer 2014, 14:177.
44. O'Shaughnessy J., Osborne C., Pippen J.E., Yoffe M., Patt D., Rocha C., Koo I.C., Sherman B.M., Bradley C. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N.Engl. J. Med. 2011, 364:205-214.
45. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N.Engl. J. Med. 2004, 351:2817-2826.
46. Patani N., Martin L.A., Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. Int. J. Cancer 2013, 133:1-13.
47. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
48. Piccart-Gebhart M.J. New developments in hormone receptor-positive disease. Oncologist 2011, 16(Suppl. 1):40-50.
49. Polley M.Y., Leung S.C., McShane L.M., Gao D., Hugh J.C., Mastropasqua M.G., Viale G., Zabaglo L.A., Penault-Llorca F., Bartlett J.M., Gown A.M., Symmans W.F., Piper T., Mehl E., Enos R.A., Hayes D.F., Dowsett M., Nielsen T.O. An international Ki67 reproducibility study. J.Natl. Cancer Inst. 2013, 105:1897-1906.
50. Polo S.E., Almouzni G. Chromatin assembly: a basic recipe with various flavours. Curr. Opin. Genet. Dev. 2006, 16:104-111.
51. Polo S.E., Theocharis S.E., Klijanienko J., Savignoni A., Asselain B., Vielh P., Almouzni G. Chromatin assembly factor-1, a marker of clinical value to distinguish quiescent from proliferating cells. Cancer Res. 2004, 64:2371-2381.
52. Qiu J.J., Guo J.J., Lv T.J., Jin H.Y., Ding J.X., Feng W.W., Zhang Y., Hua K.Q. Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer. Tumour Biol. 2013, 34:2971-2975.
53. Rajput A.B., Hu N., Varma S., Chen C.H., Ding K., Park P.C., Chapman J.A., Sengupta S.K., Madarnas Y., Elliott B.E., Feilotter H.E. Immunohistochemical assessment of expression of centromere protein-a (CENPA) in human invasive breast cancer. Cancers 2011, 3:4212-4227.
54. Ray-Gallet D., Woolfe A., Vassias I., Pellentz C., Lacoste N., Puri A., Schultz D.C., Pchelintsev N.A., Adams P.D., Jansen L.E., Almouzni G. Dynamics of histone H3 deposition invivo reveal a nucleosome gap-filling mechanism for H3.3 to maintain chromatin integrity. Mol. Cell 2011, 44:928-941.
55. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823.
56. Reyal F., van Vliet M.H., Armstrong N.J., Horlings H.M., de Visser K.E., Kok M., Teschendorff A.E., Mook S., van 't Veer L., Caldas C., Salmon R.J., van de Vijver M.J., Wessels L.F. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res. 2008, 10:R93.
57. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., Hess K.R., Stec J., Ayers M., Wagner P., Morandi P., Fan C., Rabiul I., Ross J.S., Hortobagyi G.N., Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005, 11:5678-5685.
58. Schmidt M., Victor A., Bratzel D., Boehm D., Cotarelo C., Lebrecht A., Siggelkow W., Hengstler J.G., Elsasser A., Gehrmann M., Lehr H.A., Koelbl H., von Minckwitz G., Harbeck N., Thomssen C. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann. Oncol. 2009, 20:258-264.
59. Schnitt S.J. Will molecular classification replace traditional breast pathology?. Int. J. Surg. Pathol. 2010, 18:162S-166S.
60. Seligson D.B., Horvath S., Shi T., Yu H., Tze S., Grunstein M., Kurdistani S.K. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266.
61. Servant N., Gravier E., Gestraud P., Laurent C., Paccard C., Biton A., Brito I., Mandel J., Asselain B., Barillot E., Hupe P. EMA - A R package for easy microarray data analysis. BMC Res. Notes 2010, 3:277.
62. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Lonning P.E., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
63. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L., Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003, 100:8418-8423.
64. Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A., Martiat P., Fox S.B., Harris A.L., Liu E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. USA 2003, 100:10393-10398.
65. Svotelis A., Gevry N., Grondin G., Gaudreau L. H2A.Z overexpression promotes cellular proliferation of breast cancer cells. Cell Cycle 2010, 9:364-370.
66. Tabachnick B.G., Fidell L.S. Using Multivariate Statistics 1996, Harper Collins College Publishers, New York.
67. Tian S., Roepman P., Van't Veer L.J., Bernards R., de Snoo F., Glas A.M. Biological functions of the genes in the mammaprint breast cancer profile reflect the hallmarks of cancer. Biomark. Insights 2010, 5:129-138.
68. Tobin N.P., Lindstrom L.S., Carlson J.W., Bjohle J., Bergh J., Wennmalm K. Multi-level gene expression signatures, but not binary, outperform Ki67 for the long term prognostication of breast cancer patients. Mol. Oncol. 2014, 8:741-752.
69. Tomonaga T., Matsushita K., Yamaguchi S., Oohashi T., Shimada H., Ochiai T., Yoda K., Nomura F. Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer. Cancer Res. 2003, 63:3511-3516.
70. Tsourlakis M.C., Schoop M., Plass C., Huland H., Graefen M., Steuber T., Schlomm T., Simon R., Sauter G., Sirma H., Minner S. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence. Hum. Pathol. 2013, 44:1789-1796.
71. Valente V., Serafim R.B., de Oliveira L.C., Adorni F.S., Torrieri R., Tirapelli D.P., Espreafico E.M., Oba-Shinjo S.M., Marie S.K., Paco-Larson M.L., Carlotti C.G. Modulation of HJURP (Holliday Junction-Recognizing Protein) levels is correlated with glioblastoma cells survival. PLoS One 2013, 8:e62200.
72. van 't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
73. van de Vijver M.J., He Y.D., van't Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N.Engl. J. Med. 2002, 347:1999-2009.
74. Vardabasso C., Hasson D., Ratnakumar K., Chung C.Y., Duarte L.F., Bernstein E. Histone variants: emerging players in cancer biology. Cell Mol. Life Sci. 2014, 71:379-404.
75. Varga Z., Diebold J., Dommann-Scherrer C., Frick H., Kaup D., Noske A., Obermann E., Ohlschlegel C., Padberg B., Rakozy C., Sancho Oliver S., Schobinger-Clement S., Schreiber-Facklam H., Singer G., Tapia C., Wagner U., Mastropasqua M.G., Viale G., Lehr H.A. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? AQA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One 2012, 7:e37379.
76. Weigelt B., Reis-Filho J.S. Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res. 2010, 12(Suppl. 4):S5.
77. Wirapati P., Sotiriou C., Kunkel S., Farmer P., Pradervand S., Haibe-Kains B., Desmedt C., Ignatiadis M., Sengstag T., Schutz F., Goldstein D.R., Piccart M., Delorenzi M. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10:R65.
78. Wu Q., Qian Y.M., Zhao X.L., Wang S.M., Feng X.J., Chen X.F., Zhang S.H. Expression and prognostic significance of centromere protein A in human lung adenocarcinoma. Lung Cancer 2012, 77:407-414.